Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cancer Immunotherapy & Biofluid Biopsies 2016

Ellen Beasley's Biography



Ellen Beasley, Senior Vice President, Genomic Health Inc

Ellen Beasley has over 20 years of product development and program management experience in biotechnology and genomics sciences. She brings a record of successful integration and application of bioinformatics, genetics and genomics platforms to advance and accelerate life sciences instrument, diagnostics and therapeutics product discovery and development. Ellen started her career in human genomics at the Stanford Human Genome Center and lead the team developing physical maps of the human genome. She then moved to Celera Genomics and participated in the genome sequencing and gene discovery efforts for the human genome. After the completion of the human genome, Ellen managed various discovery efforts to apply the human genome, including drug target discovery efforts, investigation of the genetic basis of autoimmune disease and companion diagnostic partnership development. Ellen then moved to Perlegen Sciences where she was SVP of R&D Operations, managing companion diagnostic programs and building the CLIA lab for commercialization of a breast cancer risk assay. In 2009, Ellen joined Life Technologies and was VP of Biological Information Systems, leading a team to develop methods and software tools to exploit the data from next generation sequencers. Since joining Genomic Health in 2013, Ellen has focused on the application of next generation technologies, including sequencing and liquid-based biopsy, to discover and develop Genomic Health’s next generation of products to serve patients living with cancer. Ellen received a B.S. in Biology from Trinity College (Hartford, CT) and a Ph.D. in Molecular Genetics & Cell Biology from The University of Chicago, she completed post-doctoral training at the Biozentrum of the University of Basel in Switzerland and Stanford University. Ellen is an inventor on approximately 170 patents.

Ellen Beasley Image

Liquid Biopsies in Cancer Disease Management

Tuesday, 1 November 2016 at 14:30

Add to Calendar ▼2016-11-01 14:30:002016-11-01 15:30:00Europe/LondonLiquid Biopsies in Cancer Disease ManagementCancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Liquid biopsies can be used to monitor tumor dynamics including recurrence or to profile individual genetic and genomic markers that are informative of treatment options.  Together, these complementary approaches provide precision solutions to help manage disease along the patient cancer journey.  These also call for different development, analytical and clinical validation strategies, as well as demonstration of clinical utility.  As these assays become more routine and move toward standard of care, it will be important to provide accurate and relevant test performance information.  I will discuss the role of standards to ensure quality and allow appropriate interpretation of test results.


Add to Calendar ▼2016-11-01 00:00:002016-11-02 00:00:00Europe/LondonCancer Immunotherapy and Biofluid Biopsies 2016Cancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com